Association study of genetic polymorphisms in GABRD with treatment response and dose in methadone maintenance treatment.

IF 1.7 4区医学 Q3 PHARMACOLOGY & PHARMACY

Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-06-23 DOI:10.2217/pme-2021-0063

Xiaohu Xie, Jun Gu, Dingding Zhuang, Xiaoyu Chen, Yun Zhou, Wenwen Shen, Longhui Li, Yue Liu, Wenjin Xu, Qingxiao Hong, Weisheng Chen, Wenhua Zhou, Huifen Liu

{"title":"Association study of genetic polymorphisms in GABRD with treatment response and dose in methadone maintenance treatment.","authors":"Xiaohu Xie, Jun Gu, Dingding Zhuang, Xiaoyu Chen, Yun Zhou, Wenwen Shen, Longhui Li, Yue Liu, Wenjin Xu, Qingxiao Hong, Weisheng Chen, Wenhua Zhou, Huifen Liu","doi":"10.2217/pme-2021-0063","DOIUrl":null,"url":null,"abstract":"Aim: This study determined if gene variants in the GABA receptor delta subunit (GABRD) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin addiction. Materials & methods: A total of 286 MMT patients were recruited and divided into response and nonresponse groups based on retention time in therapy. A total of 177 responders were classified into low dose and high dose subgroups according to the stabilized methadone dose. Four (single nucleotide polymorphisms) SNPs (rs13303344, rs4481796, rs2376805 and rs2229110) in GABRD were genotyped using the TaqMan SNP assay. Logistic regression was used to assess the genetic effects of the SNPs in MMT. Results: No significant associations were observed between the SNPs and treatment response or dose, except the frequency of haplotype ACGC at the four SNPs significantly differed between responders and nonresponders. Conclusion: The results indicated that GABRD variants may play a small role in modulating methadone treatment response.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0063","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 3

Abstract

Aim: This study determined if gene variants in the GABA receptor delta subunit (GABRD) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin addiction. Materials & methods: A total of 286 MMT patients were recruited and divided into response and nonresponse groups based on retention time in therapy. A total of 177 responders were classified into low dose and high dose subgroups according to the stabilized methadone dose. Four (single nucleotide polymorphisms) SNPs (rs13303344, rs4481796, rs2376805 and rs2229110) in GABRD were genotyped using the TaqMan SNP assay. Logistic regression was used to assess the genetic effects of the SNPs in MMT. Results: No significant associations were observed between the SNPs and treatment response or dose, except the frequency of haplotype ACGC at the four SNPs significantly differed between responders and nonresponders. Conclusion: The results indicated that GABRD variants may play a small role in modulating methadone treatment response.

查看原文本刊更多论文

GABRD基因多态性与美沙酮维持治疗疗效和剂量的相关性研究。

目的:本研究确定GABA受体δ亚基(GABRD)基因变异是否与美沙酮维持治疗(MMT)对海洛因成瘾的治疗反应和剂量相关。材料与方法:共招募286例MMT患者，根据治疗停留时间分为有反应组和无反应组。根据稳定的美沙酮剂量将177例应答者分为低剂量组和高剂量组。采用TaqMan SNP法对GABRD的4个单核苷酸多态性(rs13303344、rs4481796、rs2376805和rs2229110)进行基因分型。采用Logistic回归评估MMT中snp的遗传效应。结果:SNPs与治疗反应或剂量之间无显著相关性，除了四个SNPs的单倍型ACGC频率在应答者和无应答者之间有显著差异。结论:GABRD变异可能在调节美沙酮治疗反应中起较小作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized medicine 医学-药学

CiteScore

3.30

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.